# Enriqueta Felip

Source: https://onco.cc/people/enriqueta-felip/  
OnCo record `enriqueta-felip` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Thoracic oncologist who led IMpower010, establishing adjuvant atezolizumab in lung cancer.

## Summary

Enriqueta Felip is Head of the Thoracic Cancers Unit at Vall d'Hebron University Hospital in Barcelona and Professor at the Autonomous University of Barcelona. Her specialisms are lung cancer, targeted therapy and perioperative immunotherapy. She was principal investigator of IMpower010, reported in The Lancet, which tested adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer and established adjuvant immunotherapy in this setting. She is also a leader in trials of EGFR-, ALK- and KRAS-targeted therapy, including osimertinib. Her publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Head of Thoracic Cancers Unit, Vall d'Hebron; Professor, Autonomous University of Barcelona
- Specialisms: Lung cancer; Targeted therapy; Perioperative immunotherapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Felip%20E%5BAuthor%5D%20lung%20atezolizumab

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- targets: [ALK](https://onco.cc/targets/alk/), [EGFR](https://onco.cc/targets/egfr/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Osimertinib](https://onco.cc/drugs/osimertinib/)
- institutions: [Vall d'Hebron University Hospital / VHIO](https://onco.cc/institutions/vall-dhebron/)
- key papers: [CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery](https://onco.cc/key-papers/paper-checkmate-816-nejm-2022/), [DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer](https://onco.cc/key-papers/paper-dellphi-301-nejm-2023/), [First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer](https://onco.cc/key-papers/paper-shaw-crown-lorlatinib-crizotinib-nejm-2020/), [KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation](https://onco.cc/key-papers/paper-keynote-189-nejm-2018/), [MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-mariposa-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/enriqueta-felip.json